Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The ACR Expresses Strong Support for Dr. Anthony Fauci

From the College  |  Issue: September 2020  |  July 29, 2020

Anthony S. Fauci, MD (NIAID)

Anthony S. Fauci, MD (NIAID)

The ACR, on behalf of its more than 7,700 members of the professional rheumatology community, wishes to express strong support for Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), and his continued and close involvement in the work to address the nation’s response to the COVID-19 pandemic.

During this national public health emergency, it is vital that we adhere to sound scientific and public health guidance from medical experts, including Dr. Fauci. The ACR urges that scientific evidence shape our decisions and actions as we battle the COVID-19 pandemic. Dr. Fauci has dedicated his life to public service, leading the NIAID since 1984.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Trained in immunology, Dr. Fauci has been recognized as a Master of the ACR, one of the highest honors the College bestows. He has earned the respect of the medical and scientific community and has proven his commitment to relying on science and the best available data as we work collectively to preserve public health in these challenging times.

“Dr. Fauci has a long history with rheumatology,” says Philip Seo, MD, MHS, an associate professor of medicine at the Johns Hopkins University School of Medicine, Baltimore, director of both the Johns Hopkins Vasculitis Center and the Johns Hopkins Rheumatology Fellowship Program and physician editor of The Rheumatologist. “When Dr. Fauci first arrived at the NIH as a fellow in immunology and infectious diseases, he was fascinated by patients who had presented with a prolonged fever of unknown origin. A subset of these patients had systemic vasculitis. He received permission from his mentor, Sheldon M. Wolff, MD, to follow these patients closely. Because patients with granulomatosis with polyangiitis (GPA) had high morbidity and mortality, they elected to try a novel approach: low-dose cyclophosphamide in combination with alternating doses of prednisone. The response was dramatic, and the Fauci-Wolff protocol transformed GPA into a chronic disease, characterized by cycles of relapse and remission. Almost all subsequent treatments for systemic vasculitis owe some debt to this initial experience.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR lauds the government’s financial commitment to vaccine development to address the COVID-19 pandemic. In addition, Dr. Fauci, as well as other long-term professional leaders from the CDC, FDA, and NIH, should guide and inform the response of the government and the American people as we all work to control the spread of the SARS-CoV-2 virus. By following their collective lead, we have the best chance for a speedier mitigation of this deadly virus.

Page: 1 2 | Single Page
Share: 

Filed under:Professional Topics Tagged with:ACR Convergence 2020Anthony S. FauciCOVID-19

Related Articles

    From AIDS to Zika: ‘What’s next?’ asked Dr. Anthony Fauci in keynote address at the 2017 ACR/ARHP Annual Meeting

    November 5, 2017

    SAN DIEGO—The 2017 ACR/ARHP Annual Meeting kicked off on Nov. 4 with a rousing presentation by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID). A terrorist attack on U.S. soil, hurricane, cyberattack and pandemic were the four scenarios played out in late 2016, when NIAID conducted a tabletop…

    Dr. Fauci Talks COVID-19 with the ACR

    November 10, 2020

    ACR CONVERGENCE 2020—At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984, delivered a special lecture on COVID-19, from virology to therapy to vaccine development. Novel Coronavirus, Familiar Vectors When Chinese physicians first reported infections by what…

    Inaugural ACR Distinguished Global Public Health Award Presented to Dr. Fauci

    November 11, 2020

    ACR CONVERGENCE 2020—At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, ACR President Ellen M. Gravallese, MD, chief of the Division of Rheumatology, Inflammation and Immunity at Brigham and Women’s Hospital, Boston, presented the inaugural ACR Distinguished Global Public Health Award to Anthony S. Fauci, MD, director of the National Institute of Allergy…

    The 2020 ARP Merit Awards & ACR Distinguished Fellows

    December 14, 2020

    During ACR Convergence 2020 in early November, the ACR and ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards and the ACR’s Distinguished Fellows. In addition, we bring you the first ever…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences